… complications from antithrombotic treatment remain substantial. … stroke prevention for
patients with atrial fibrillation during the past 30 years and focus on novel diagnostic and treatment …

… Non-vitamin K oral antagonist anticoagulants (NOACs) have been widely used in stroke
prevention in atrial fibrillation (SPAF). The aim of this study was to compare the …

… assess the cost effectiveness of apixaban versus edoxaban in the prevention of stroke and
… Spain, this study aimed to assess the cost effectiveness of apixaban versus edoxaban for the …

… cost-effectiveness plane … costs per patient and benefits per patient of atrial fibrillation
screening compared with no screening. Atrial fibrillation screening was found to be cost-effective if …

… the cost-effectiveness of these devices is required. The objective of this systematic review is
to synthesize the published economic literature on the cost-effectiveness … cryptogenic stroke. …

… NOACs) and warfarin care bundles (eg genotyping… care for stroke prevention in patients
with atrial fibrillation (AF). We aim to evaluate the cost-effectiveness of NOACs and warfarin care …

… , disabling stroke, serious bleeding, or cardiac arrest compared with drug therapy by
intention-to-treat, but did improve the quality of life and freedom from atrial fibrillation recurrence. In …

… ), patients with acute ischaemic stroke and patients with an … stroke prevention strategies,
including left atrial appendage occlusion, in patients with atrial fibrillation at high risk of stroke …

… about topics “stroke”, “atrial fibrillation and stroke” and “share of undetected atrial fibrillation”.
… For Switzerland, the cost effectiveness for the use of anticoagulant therapy was estimated …

… 34% of eligible patients with atrial fibrillation with guideline‐indicated treatment rates >80%
for … ‐detected atrial fibrillation cases. Economic modeling showed that the program was cost‐…